National Research Corp. (NRCIB) Downgraded by Zacks Investment Research
National Research Corp. (NASDAQ:NRCIB) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “National Research Corporation is a leading provider of ongoing survey-based performance measurement, analysis and tracking services to the healthcare industry. The company addresses the growing need of healthcare providers and payers to measure the care outcomes, specifically satisfaction and health status, of their patients and/or members. The company’s primary types of information services are renewable performance tracking services, custom research and a renewable syndicated service. “
National Research Corp. (NASDAQ:NRCIB) opened at 35.23 on Wednesday. National Research Corp. has a 1-year low of $31.88 and a 1-year high of $44.60. The company has a market cap of $853.31 million, a price-to-earnings ratio of 43.28 and a beta of 0.28. The firm’s 50-day moving average price is $34.90 and its 200-day moving average price is $35.27.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/national-research-corp-nrcib-downgraded-by-zacks-investment-research.html
National Research Corp. (NASDAQ:NRCIB) last issued its quarterly earnings data on Tuesday, August 2nd. The company reported $0.18 EPS for the quarter, hitting analysts’ consensus estimates of $0.18. National Research Corp. had a return on equity of 33.74% and a net margin of 18.75%. Equities research analysts forecast that National Research Corp. will post $0.82 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 14th. Stockholders of record on Friday, September 30th will be paid a $0.48 dividend. The ex-dividend date is Wednesday, September 28th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 5.45%. National Research Corp.’s payout ratio is presently 408.52%.
In other news, CEO Michael D. Hays sold 3,533 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $16.19, for a total value of $57,199.27. Following the transaction, the chief executive officer now owns 6,467,744 shares in the company, valued at approximately $104,712,775.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 39.09% of the stock is owned by insiders.
An institutional investor recently bought a new position in National Research Corp. stock. Willis Investment Counsel acquired a new stake in shares of National Research Corp. (NASDAQ:NRCIB) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 13,329 shares of the company’s stock, valued at approximately $442,000. Willis Investment Counsel owned 0.06% of National Research Corp. at the end of the most recent quarter. Institutional investors own 2.90% of the company’s stock.
National Research Corp. is a business services company in the Health Care Services industry.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for National Research Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research Corp. and related companies with MarketBeat.com's FREE daily email newsletter.